nach oben

Rheumatology International

Erschienen in:

03.01.2021 | COVID-19 | Review Zur Zeit gratis

Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic

verfasst von: Sakir Ahmed, Armen Yuri Gasparyan, Olena Zimba

Erschienen in: Rheumatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Comorbidities in rheumatic and musculoskeletal diseases (RMDs) not only increase morbidity and mortality but also confound disease activity, limit drug usage and increase chances of severe infections or drug-associated adverse effects. Most RMDs lead to accelerated atherosclerosis and variable manifestations of the metabolic syndrome. Literature on COVID-19 in patients with RMDs, and the effects of various comorbidities on COVID-19 was reviewed. The initial data of COVID-19 infections in RMDs have not shown an increased risk for severe disease or the use of different immunosuppression. However, there are some emerging data that patients with RMDs and comorbidities may fare worse. Various meta-analyses have reiterated that pre-existing hypertension, cardiovascular disease, stroke, diabetes, chronic kidney disease, heart failure, lung disease or obesity predispose to increased COVID-19 mortality. All these comorbidities are commonly encountered in the various RMDs. Presence of comorbidities in RMDs pose a greater risk than the RMDs themselves. A risk score based on comorbidities in RMDs should be developed to predict severe COVID-19 and death. Additionally, there should be active management of such comorbidities to mitigate these risks. The pandemic must draw our attention towards, and not away from, comorbidities.

Moltó A, Dougados M (2014) Comorbidity indices. Clin Exp Rheumatol 32:S131-134

Baillet A, Gossec L, Carmona L et al (2016) Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 75:965–973. https://doi.org/10.1136/annrheumdis-2016-209233CrossRefPubMed

Schieir O, Tosevski C, Glazier RH et al (2017) Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis 76:1396–1404. https://doi.org/10.1136/annrheumdis-2016-210275CrossRefPubMed

Edwards RR, Cahalan C, Calahan C et al (2011) Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 7:216–224. https://doi.org/10.1038/nrrheum.2011.2CrossRefPubMed

Straub RH (2017) The brain and immune system prompt energy shortage in chronic inflammation and ageing. Nat Rev Rheumatol 13:743–751. https://doi.org/10.1038/nrrheum.2017.172CrossRefPubMed

Simon TA, Thompson A, Gandhi KK et al (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. https://doi.org/10.1186/s13075-015-0728-9CrossRefPubMedPubMedCentral

Santos CS, Morales CM, Álvarez ED et al (2020) Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol 39:2789–2796. https://doi.org/10.1007/s10067-020-05301-2CrossRefPubMedPubMedCentral

Onuora S (2020) New data emerging on outcomes for patients with COVID-19 and rheumatic diseases. Nat Rev Rheumatol 16:407. https://doi.org/10.1038/s41584-020-0463-8CrossRefPubMedPubMedCentral

Gianfrancesco M, Hyrich KL, Al-Adely S et al (2020) Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 79:859–866. https://doi.org/10.1136/annrheumdis-2020-217871CrossRefPubMed

10.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3CrossRefPubMed

11.

Ye C, Cai S, Shen G et al (2020) Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis 79:1007–1013. https://doi.org/10.1136/annrheumdis-2020-217627CrossRefPubMed

12.

Pablos JL, Abasolo L, Alvaro-Gracia JM et al (2020) Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis 79:1170–1173. https://doi.org/10.1136/annrheumdis-2020-217763CrossRefPubMed

13.

Kipps S, Paul A, Vasireddy S (2020) Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic? Clin Rheumatol. https://doi.org/10.1007/s10067-020-05494-6CrossRefPubMedPubMedCentral

14.

D’Silva KM, Serling-Boyd N, Wallwork R et al (2020) Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot.’ Ann Rheum Dis 79:1156–1162. https://doi.org/10.1136/annrheumdis-2020-217888CrossRefPubMed

15.

Sanchez-Piedra C, Diaz-Torne C, Manero J et al (2020) Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis 79:988–990. https://doi.org/10.1136/annrheumdis-2020-217948CrossRefPubMed

16.

Freites Nuñez DD, Leon L, Mucientes A et al (2020) Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217984CrossRefPubMed

17.

Pablos JL, Galindo M, Carmona L et al (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218296CrossRefPubMed

18.

Nuño L, Navarro MN, Bonilla G et al (2020) Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218054CrossRefPubMed

19.

Scirè CA, Carrara G, Zanetti A et al (2020) COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol 38:748–753PubMed

20.

Cheng C, Li C, Zhao T et al (2020) COVID-19 with rheumatic diseases: a report of 5 cases. Clin Rheumatol 39:2025–2029. https://doi.org/10.1007/s10067-020-05160-xCrossRefPubMedPubMedCentral

21.

Quartuccio L, Valent F, Pasut E et al (2020) Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine 87:439–443. https://doi.org/10.1016/j.jbspin.2020.05.003CrossRefPubMedPubMedCentral

22.

Hasseli R, Mueller-Ladner U, Schmeiser T et al (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open 6:e001332. https://doi.org/10.1136/rmdopen-2020-001332CrossRefPubMedPubMedCentral

23.

Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R (2020) Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 40:1707–1716. https://doi.org/10.1007/s00296-020-04635-zCrossRefPubMedPubMedCentral

24.

Montero F, Martínez-Barrio J, Serrano-Benavente B et al (2020) Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 40:1593–1598. https://doi.org/10.1007/s00296-020-04676-4CrossRefPubMedPubMedCentral

25.

Loarce-Martos J, García-Fernández A, López-Gutiérrez F et al (2020) High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int 40:2015–2021. https://doi.org/10.1007/s00296-020-04699-xCrossRefPubMed

26.

So H, MAK JW-Y, SO J et al (2020) Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study. Semin Arthritis Rheum 50:885–889. https://doi.org/10.1016/j.semarthrit.2020.07.012CrossRefPubMedPubMedCentral

27.

Sharmeen S, Elghawy A, Zarlasht F, Yao Q (2020) COVID-19 in rheumatic disease patients on immunosuppressive agents. Semin Arthritis Rheum 50:680–686. https://doi.org/10.1016/j.semarthrit.2020.05.010CrossRefPubMedPubMedCentral

28.

Michelena X, Borrell H, López-Corbeto M et al (2020) Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 50:564–570. https://doi.org/10.1016/j.semarthrit.2020.05.001CrossRefPubMedPubMedCentral

29.

Fredi M, Cavazzana I, Moschetti L et al (2020) COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study. Lancet Rheumatol 2:e549–e556. https://doi.org/10.1016/S2665-9913(20)30169-7CrossRefPubMedPubMedCentral

30.

Zhong J, Shen G, Yang H et al (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2:e557–e564. https://doi.org/10.1016/S2665-9913(20)30227-7CrossRefPubMedPubMedCentral

31.

Pistone A, Tant L, Soyfoo MS (2020) Clinical course of COVID-19 infection in inflammatory rheumatological patients: a monocentric Belgian experience. Rheumatol Adv Pract 4:rkaa055. https://doi.org/10.1093/rap/rkaa055CrossRefPubMedPubMedCentral

32.

Tiendrébéogo WJS, Kaboré F, Diendéré EA, Ouedraogo DD (2020) Case series of chronic inflammatory rheumatic disease patients infected by coronavirus disease 2019 (COVID-19). Case Rep Rheumatol 2020:8860492. https://doi.org/10.1155/2020/8860492CrossRef

33.

Lwin M, Holroyd C, Wallis D et al (2020) Does COVID-19 cause an increased risk of hospitalisation or death in patients with inflammatory rheumatic diseases treated with bDMARDs or tsDMARDs? Rheumatol Adv Pract. https://doi.org/10.1093/rap/rkaa061CrossRefPubMedPubMedCentral

34.

Murray K, Quinn S, Turk M et al (2020) COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. Rheumatology (Oxford) keaa694. https://doi.org/10.1093/rheumatology/keaa694CrossRef

35.

Costantino F, Bahier L, Tarancón LC et al (2020) COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. https://doi.org/10.1016/j.jbspin.2020.105095CrossRefPubMedPubMedCentral

36.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRef

37.

Palaiodimos L, Kokkinidis DG, Li W et al. (2020) Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx New York. Metabolism 108:154262. DOI: 10.1016/j.metabol.2020.154262CrossRefPubMedPubMedCentral

38.

Price-Haywood EG, Burton J, Fort D, Seooane L (2020) Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med 382:2534–2543. https://doi.org/10.1056/NEJMsa2011686CrossRefPubMed

39.

Ssentongo P, Ssentongo AE, Heilbrunn ES et al (2020) Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS ONE 15:e0238215. https://doi.org/10.1371/journal.pone.0238215CrossRefPubMedPubMedCentral

40.

Zheng Z, Peng F, Xu B et al (2020) Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 81:e16–e25. https://doi.org/10.1016/j.jinf.2020.04.021CrossRefPubMedPubMedCentral

41.

Pranata R, Huang I, Lim MA et al (2020) Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 29:104949. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104949CrossRef

42.

Yang J, Zheng Y, Gou X et al (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95. https://doi.org/10.1016/j.ijid.2020.03.017CrossRefPubMedPubMedCentral

43.

Li B, Yang J, Zhao F et al (2020) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 109:531–538. https://doi.org/10.1007/s00392-020-01626-9CrossRefPubMed

44.

Alqahtani JS, Oyelade T, Aldhahir AM et al (2020) Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS ONE 15:e0233147. https://doi.org/10.1371/journal.pone.0233147CrossRefPubMedPubMedCentral

45.

Huang I, Lim MA, Pranata R (2020) Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 14:395–403. https://doi.org/10.1016/j.dsx.2020.04.018CrossRefPubMedPubMedCentral

46.

Wu Z, Tang Y, Cheng Q (2020) Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. https://doi.org/10.1007/s00592-020-01546-0CrossRefPubMedPubMedCentral

47.

Roncon L, Zuin M, Rigatelli G, Zuliani G (2020) Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol Off Publ Pan Am Soc Clin Virol 127:104354. https://doi.org/10.1016/j.jcv.2020.104354CrossRef

48.

Fadini GP, Morieri ML, Longato E, Avogaro A (2020) Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 43:867–869. https://doi.org/10.1007/s40618-020-01236-2CrossRefPubMedPubMedCentral

49.

Barrera FJ, Shekhar S, Wurth R et al (2020) Prevalence of diabetes and hypertension and their associated risks for poor outcomes in COVID-19 patients. J Endocr Soc 4:102. https://doi.org/10.1210/jendso/bvaa102CrossRef

50.

Kumar A, Arora A, Sharma P et al (2020) Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 14:535–545. https://doi.org/10.1016/j.dsx.2020.04.044CrossRefPubMedPubMedCentral

51.

Liang X, Shi L, Wang Y et al (2020) The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates. J Infect 81:e44–e47. https://doi.org/10.1016/j.jinf.2020.06.060CrossRefPubMedPubMedCentral

52.

Zhang J, Wu J, Sun X et al (2020) Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol Infect 148:e106. https://doi.org/10.1017/S095026882000117XCrossRefPubMed

53.

Zuin M, Rigatelli G, Zuliani G et al (2020) Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect 81:e84–e86. https://doi.org/10.1016/j.jinf.2020.03.059CrossRefPubMedPubMedCentral

54.

Pranata R, Lim MA, Huang I et al (2020) Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin-Angiotensin-Aldosterone Syst JRAAS 21:1470320320926899 doi: https://doi.org/10.1177/1470320320926899

55.

Hussain A, Mahawar K, Xia Z et al (2020) Obesity and mortality of COVID-19. Meta-analysis Obes Res Clin Pract 14:295–300. https://doi.org/10.1016/j.orcp.2020.07.002CrossRefPubMed

56.

Liu M, Gao Y, Zhang Y et al (2020) The association between severe or dead COVID-19 and autoimmune diseases: a systematic review and meta-analysis. J Infect 81:e93–e95. https://doi.org/10.1016/j.jinf.2020.05.065CrossRefPubMedPubMedCentral

57.

Batko B, Urbański K, Świerkot J et al (2019) Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clin Rheumatol 38:2473–2481. https://doi.org/10.1007/s10067-019-04579-1CrossRefPubMed

58.

Batu ED, Özen S (2020) Implications of COVID-19 in pediatric rheumatology. Rheumatol Int 40:1193–1213. https://doi.org/10.1007/s00296-020-04612-6CrossRefPubMedPubMedCentral

59.

Kerekes G, Nurmohamed MT, González-Gay MA et al (2014) Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol 10:691–696. https://doi.org/10.1038/nrrheum.2014.121CrossRefPubMed

60.

Hallajzadeh J, Safiri S, Mansournia MA et al (2017) Metabolic syndrome and its components among rheumatoid arthritis patients: a comprehensive updated systematic review and meta-analysis. PLoS ONE 12:e0170361. https://doi.org/10.1371/journal.pone.0170361CrossRefPubMedPubMedCentral

61.

Castro LL, Lanna CCD, Rocha MP et al (2018) Recognition and control of hypertension, diabetes, and dyslipidemia in patients with rheumatoid arthritis. Rheumatol Int 38:1437–1442. https://doi.org/10.1007/s00296-018-4084-3CrossRefPubMed

62.

de Resende Guimarães MFB, Rodrigues CEM, Gomes KWP et al (2019) High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study. Adv Rheumatol 59:44. https://doi.org/10.1186/s42358-019-0089-1CrossRef

63.

van Breukelen-van der Stoep DF, van Zeben D, Klop B et al (2016) Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology (Oxford) 55:1210–1216. https://doi.org/10.1093/rheumatology/kew039CrossRef

64.

Pappas DA, Nyberg F, Kremer JM et al (2018) Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. Clin Rheumatol 37:2331–2340. https://doi.org/10.1007/s10067-018-4113-3CrossRefPubMed

65.

Albrecht K, Luque Ramos A, Hoffmann F et al (2018) High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford) 57:329–336. https://doi.org/10.1093/rheumatology/kex414CrossRef

66.

Norton S, Koduri G, Nikiphorou E et al (2013) A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and their impact on outcome. Rheumatology (Oxford) 52:99–110. https://doi.org/10.1093/rheumatology/kes262CrossRef

67.

Spagnolo P, Lee JS, Sverzellati N et al (2018) The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 70:1544–1554. https://doi.org/10.1002/art.40574CrossRefPubMed

68.

Crowson CS, Rollefstad S, Ikdahl E et al (2018) Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 77:48–54. https://doi.org/10.1136/annrheumdis-2017-211735CrossRefPubMed

69.

Ortolan A, Lorenzin M, Tadiotto G et al (2019) Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol 38:2843–2850. https://doi.org/10.1007/s10067-019-04646-7CrossRefPubMed

70.

Özkan SG, Yazısız H, Behlül A et al (2017) Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis. Eur J Rheumatol 4:40–45. https://doi.org/10.5152/eurjrheum.2017.16052CrossRefPubMedPubMedCentral

71.

Caso F, Del Puente A, Oliviero F et al (2018) Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol 37:579–586. https://doi.org/10.1007/s10067-017-3975-0CrossRefPubMed

72.

Favarato MH, Mease P, Gonçalves CR et al (2014) Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol 32:182–187PubMed

73.

Queiro R, Lorenzo A, Tejón P et al (2019) Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. Clin Rheumatol 38:2063–2068. https://doi.org/10.1007/s10067-019-04519-zCrossRefPubMed

74.

Queiro R, Lorenzo A, Tejón P et al (2019) Obesity in psoriatic arthritis: comparative prevalence and associated factors. Medicine (Baltimore) 98:e16400. https://doi.org/10.1097/MD.0000000000016400CrossRef

75.

Radner H, Lesperance T, Accortt NA, Solomon DH (2017) Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res 69:1510–1518. https://doi.org/10.1002/acr.23171CrossRef

76.

Dubreuil M, Rho YH, Man A et al (2014) Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 53:346–352. https://doi.org/10.1093/rheumatology/ket343CrossRef

77.

Queiro R, Lorenzo A, Pardo E et al (2018) Prevalence and type II diabetes-associated factors in psoriatic arthritis. Clin Rheumatol 37:1059–1064. https://doi.org/10.1007/s10067-018-4042-1CrossRefPubMed

78.

Shen J, Wong K-T, Cheng IT et al (2017) Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 76:1237–1244. https://doi.org/10.1136/annrheumdis-2016-210390CrossRefPubMed

79.

Cheng IT, Wong KT, Li EK et al (2020) Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. RMD Open 6:e001364. https://doi.org/10.1136/rmdopen-2020-001364CrossRefPubMedPubMedCentral

80.

Ljung L, Sundström B, Smeds J et al (2018) Patterns of comorbidity and disease characteristics among patients with ankylosing spondylitis—a cross-sectional study. Clin Rheumatol 37:647–653. https://doi.org/10.1007/s10067-017-3894-0CrossRefPubMed

81.

Derakhshan MH, Goodson NJ, Packham JC et al (2019) Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J Rheumatol 46:701–709. https://doi.org/10.3899/jrheum.180538CrossRefPubMed

82.

Berg IJ, Semb AG, van der Heijde D et al (2014) Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a cross-sectional study. Semin Arthritis Rheum 44:309–313. https://doi.org/10.1016/j.semarthrit.2014.05.017CrossRefPubMed

83.

Klingberg E, Sveälv BG, Täng MS et al (2015) Aortic regurgitation is common in ankylosing spondylitis: time for routine echocardiography evaluation? Am J Med 128:1244-1250.e1. https://doi.org/10.1016/j.amjmed.2015.04.032CrossRefPubMed

84.

Mageau A, Timsit J-F, Perrozziello A et al (2019) The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study. Autoimmun Rev 18:733–737. https://doi.org/10.1016/j.autrev.2019.05.011CrossRefPubMed

85.

Davidson A (2016) What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 12:143–153. https://doi.org/10.1038/nrrheum.2015.159CrossRefPubMed

86.

Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C et al (2019) Systemic lupus erythematosus and hypertension. Autoimmun Rev 18:102371. https://doi.org/10.1016/j.autrev.2019.102371CrossRefPubMed

87.

Chen H-A, Hsu T-C, Yang S-C et al (2019) Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study. Arthritis Res Ther 21:82. https://doi.org/10.1186/s13075-019-1868-0CrossRefPubMedPubMedCentral

88.

Chazal T, Kerneis M, Guedeney P et al (2020) Coronary artery disease in systemic lupus: a case-controlled angiographic study. Autoimmun Rev 19:102427. https://doi.org/10.1016/j.autrev.2019.102427CrossRefPubMed

89.

Perelas A, Arrossi AV, Highland KB (2019) Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med 40:501–518. https://doi.org/10.1016/j.ccm.2019.05.001CrossRefPubMed

90.

Khanna D, Tashkin DP, Denton CP et al (2019) Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 58:567–579. https://doi.org/10.1093/rheumatology/key151CrossRef

91.

Young A, Vummidi D, Visovatti S et al (2019) Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol 71:1339–1349. https://doi.org/10.1002/art.40862CrossRefPubMedPubMedCentral

92.

Jain A, Srinivas BH, Emmanuel D et al (2018) Renal involvement in primary Sjogren’s syndrome: a prospective cohort study. Rheumatol Int 38:2251–2262. https://doi.org/10.1007/s00296-018-4118-xCrossRefPubMed

93.

Roca F, Dominique S, Schmidt J et al (2017) Interstitial lung disease in primary Sjögren’s syndrome. Autoimmun Rev 16:48–54. https://doi.org/10.1016/j.autrev.2016.09.017CrossRefPubMed

94.

Alba MA, Flores-Suárez LF, Henderson AG et al (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16:722–729. https://doi.org/10.1016/j.autrev.2017.05.008CrossRefPubMedPubMedCentral

95.

Moiseev S, Novikov P, Jayne D, Mukhin N (2017) End-stage renal disease in ANCA-associated vasculitis. Nephrol Dial Transplant 32:248–253. https://doi.org/10.1093/ndt/gfw046CrossRefPubMed

96.

Qi Y, Yang L, Zhang H et al (2018) The presentation and management of hypertension in a large cohort of Takayasu arteritis. Clin Rheumatol 37:2781–2788. https://doi.org/10.1007/s10067-017-3947-4CrossRefPubMed

97.

Jiang P, Li H, Li X (2015) Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol 33:115–121PubMed

98.

Nicolau J, Lequerré T, Bacquet H, Vittecoq O (2017) Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine 84:411–416. https://doi.org/10.1016/j.jbspin.2016.09.001CrossRefPubMed

99.

Liu Y, Hazlewood GS, Kaplan GG et al (2017) Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69:157–165. https://doi.org/10.1002/acr.22932CrossRef

100.

Yim KM, Armstrong AW (2017) Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms. Rheumatol Int 37: 97–105. https://doi.org/10.1007/s00296-016-3487-2CrossRefPubMed

101.

Prasad M, Hermann J, Gabriel SE et al (2015) Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12:168–176. https://doi.org/10.1038/nrcardio.2014.206CrossRefPubMed

102.

Lee KS, Kronbichler A, Eisenhut M et al (2018) Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians. Autoimmun Rev 17:201–214. https://doi.org/10.1016/j.autrev.2017.12.001CrossRefPubMed

103.

Ahmed S, Zimba O, Gasparyan AY (2020) Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad. Clin Rheumatol 39:2529–2543. https://doi.org/10.1007/s10067-020-05275-1CrossRef

104.

Giacomelli R, Liakouli V, Berardicurti O et al (2017) Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatol Int 37:853–863. https://doi.org/10.1007/s00296-016-3636-7CrossRefPubMed

105.

Sánchez-Cano D, Ortego-Centeno N, Callejas JL et al (2018) Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int 38:363–374. https://doi.org/10.1007/s00296-017-3916-xCrossRefPubMed

106.

Reiseter S, Gunnarsson R, Mogens Aaløkken T et al (2018) Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford) 57:255–262. https://doi.org/10.1093/rheumatology/kex077CrossRef

107.

Lega JC, Reynaud Q, Belot A et al (2015) Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 24:216–238. https://doi.org/10.1183/16000617.00002015CrossRefPubMed

108.

Guisado-Vasco P, Silva M, Duarte-Millán MA et al (2019) Quantitative assessment of interstitial lung disease in Sjögren’s syndrome. PLoS ONE 14:e0224772. https://doi.org/10.1371/journal.pone.0224772CrossRefPubMedPubMedCentral

109.

Sambataro G, Ferro F, Orlandi M et al (2020) Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren’s syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev 19:102447. https://doi.org/10.1016/j.autrev.2019.102447CrossRefPubMed

110.

Raksasuk S, Ungprasert P (2020) Patients with rheumatoid arthritis have an increased risk of incident chronic kidney disease: a systematic review and meta-analysis of cohort studies. Int Urol Nephrol 52:147–154. https://doi.org/10.1007/s11255-019-02346-4CrossRefPubMed

111.

Kapoor T, Bathon J (2018) Renal manifestations of rheumatoid arthritis. Rheum Dis Clin North Am 44:571–584. https://doi.org/10.1016/j.rdc.2018.06.008CrossRefPubMed

112.

Bertrand D, Dehay J, Ott J et al (2017) Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transpl Int 30:256–265. https://doi.org/10.1111/tri.12923CrossRef

113.

Matcham F, Rayner L, Steer S, Hotopf M (2013) The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 52:2136–2148. https://doi.org/10.1093/rheumatology/ket169CrossRef

114.

Nerurkar L, Siebert S, McInnes IB, Cavanagh J (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6:164–173. https://doi.org/10.1016/S2215-0366(18)30255-4CrossRefPubMed

115.

Blume J, Douglas SD, Evans DL (2011) Immune suppression and immune activation in depression. Brain Behav Immun 25:221–229. https://doi.org/10.1016/j.bbi.2010.10.008CrossRefPubMed

116.

Ambrée O, Ruland C, Scheu S et al (2018) Alterations of the innate immune system in susceptibility and resilience after social defeat stress. Front Behav Neurosci 12:141. https://doi.org/10.3389/fnbeh.2018.00141CrossRefPubMedPubMedCentral

117.

Askim Å, Gustad LT, Paulsen J et al (2018) Anxiety and depression symptoms in a general population and future risk of bloodstream infection: the HUNT study. Psychosom Med 80:673–679. https://doi.org/10.1097/PSY.0000000000000619CrossRefPubMed

118.

Hsu C-Y, Ko C-H, Wang J-L et al (2019) Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther 21:211. https://doi.org/10.1186/s13075-019-1997-5CrossRefPubMedPubMedCentral

119.

Bryant PA, Baddley JW (2017) Opportunistic infections in biological therapy, risk and prevention. Rheum Dis Clin North Am 43:27–41. https://doi.org/10.1016/j.rdc.2016.09.005CrossRefPubMed

120.

Shi Y, Wu Y, Ren Y et al (2019) Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis 22:1361–1370. https://doi.org/10.1111/1756-185X.13596CrossRefPubMed

121.

Meroni PL, Zavaglia D, Girmenia C (2018) Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 36:317–328PubMed

122.

Furer V, Rondaan C, Heijstek M et al (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5:e001041. https://doi.org/10.1136/rmdopen-2019-001041CrossRefPubMedPubMedCentral

123.

Hippisley-Cox J, Young D, Coupland C et al (2020) Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 106:1503–1511. https://doi.org/10.1136/heartjnl-2020-317393CrossRefPubMed

124.

Baral R, White M, Vassiliou VS (2020) Effect of Renin-Angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients. Curr Atheroscler Rep 22:61. https://doi.org/10.1007/s11883-020-00880-6CrossRefPubMedPubMedCentral

125.

Kitas GD, Nightingale P, Armitage J et al (2019) A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ 71:1437–1449. https://doi.org/10.1002/art.40892CrossRef

126.

Toloza S, Urowitz MB, Gladman DD (2007) Should all patients with systemic lupus erythematosus receive cardioprotection with statins? Nat Clin Pract Rheumatol 3:536–537. https://doi.org/10.1038/ncprheum0593CrossRefPubMed

127.

Lee KCH, Sewa DW, Phua GC (2020) Potential role of statins in COVID-19. Int J Infect Dis 96:615–617. https://doi.org/10.1016/j.ijid.2020.05.115CrossRefPubMedPubMedCentral

128.

Zhang X-J, Qin J-J, Cheng X et al (2020) In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 32:176-187.e4. https://doi.org/10.1016/j.cmet.2020.06.015CrossRefPubMedPubMedCentral

129.

Floris A, Piga M, Mangoni AA et al (2018) Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflamm 2018:3424136. https://doi.org/10.1155/2018/3424136CrossRefPubMedPubMedCentral

130.

Miranda S, Billoir P, Damian L et al (2019) Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction. PLoS ONE 14:e0212614. https://doi.org/10.1371/journal.pone.0212614CrossRefPubMedPubMedCentral

131.

Casian A, Sangle SR, D’Cruz DP (2018) New use for an old treatment: hydroxychloroquine as a potential treatment for systemic vasculitis. Autoimmun Rev 17:660–664. https://doi.org/10.1016/j.autrev.2018.01.016CrossRefPubMed

132.

Ackermann M, Verleden SE, Kuehnel M et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med 383:120–128. https://doi.org/10.1056/NEJMoa2015432CrossRefPubMedPubMedCentral

133.

Gendelman O, Amital H, Bragazzi NL et al (2020) Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev 19:102566. https://doi.org/10.1016/j.autrev.2020.102566CrossRefPubMedPubMedCentral

134.

Gil MR, Barouqa M, Szymanski J et al (2020) Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 3:e2017539–e2017539. https://doi.org/10.1001/jamanetworkopen.2020.17539CrossRef

135.

Mitchell F (2020) Vitamin-D and COVID-19: do deficient risk a poorer outcome? Lancet Diabetes Endocrinol 8:570. https://doi.org/10.1016/S2213-8587(20)30183-2CrossRefPubMedPubMedCentral

136.

Baktash V, Hosack T, Patel N et al (2020) Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J. https://doi.org/10.1136/postgradmedj-2020-138712CrossRefPubMed

137.

Carter SJ, Baranauskas MN, Fly AD (2020) Considerations for obesity, vitamin D, and physical activity amid the COVID-19 pandemic. Obes Silver Spring Md 28:1176–1177. https://doi.org/10.1002/oby.22838CrossRef

138.

Rossini M, Gatti D, Viapiana O et al (2014) Vitamin D and rheumatic diseases. Reumatismo 66:153–170. https://doi.org/10.4081/reumatismo.2014.788CrossRefPubMed

139.

Franco AS, Freitas TQ, Bernardo WM, Pereira RMR (2017) Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: a systematic review and meta-analysis. Medicine (Baltimore) 96:e7024. https://doi.org/10.1097/MD.0000000000007024CrossRef

140.

Blanch-Rubió J, Soldevila-Domenech N, Tío L et al (2020) Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY) 12:19923–19937. https://doi.org/10.18632/aging.104117CrossRef

141.

Khoramipour K, Basereh A, Hekmatikar AA, et al (2020) Physical activity and nutrition guidelines to help with the fight against COVID-19. J Sports Sci. https://doi.org/10.1080/02640414.2020.1807089CrossRefPubMed

142.

Cramer H, Lauche R, Langhorst J, Dobos G (2013) Yoga for depression: a systematic review and meta-analysis. Depress Anxiety 30:1068–1083. https://doi.org/10.1002/da.22166CrossRefPubMed

143.

Shah S, Danda D, Kavadichanda C et al (2020) Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. Rheumatol Int 40:1539–1554. https://doi.org/10.1007/s00296-020-04639-9CrossRefPubMedPubMedCentral

144.

Galeotti C, Bayry J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16:413–414. https://doi.org/10.1038/s41584-020-0448-7CrossRefPubMed

145.

Schett G, Manger B, Simon D, Caporali R (2020) COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol 16:465–470. https://doi.org/10.1038/s41584-020-0451-zCrossRefPubMedPubMedCentral

146.

Saricaoglu EM, Hasanoglu I, Guner R (2020) The first reactive arthritis case associated with COVID-19. J Med Virol. https://doi.org/10.1002/jmv.26296CrossRefPubMedPubMedCentral

147.

Ono K, Kishimoto M, Shimasaki T et al (2020) Reactive arthritis after COVID-19 infection. RMD Open 6:e001350. https://doi.org/10.1136/rmdopen-2020-001350CrossRefPubMedPubMedCentral

148.

Haberman RH, Castillo R, Chen A et al (2020) COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes. Arthritis Rheumatol Hoboken NJ. https://doi.org/10.1002/art.41456CrossRef

149.

Puntmann VO, Carerj ML, Wieters I et al (2020) Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol 5:1265–1273. https://doi.org/10.1001/jamacardio.2020.3557CrossRefPubMedPubMedCentral

150.

Huang L, Zhao P, Tang D et al (2020) Cardiac involvement in patients recovered from COVID-19 identified using magnetic resonance imaging. JACC Cardiovasc Imaging 13:2330–2339. https://doi.org/10.1016/j.jcmg.2020.05.004CrossRefPubMedPubMedCentral

151.

Ojo AS, Balogun SA, Williams OT, Ojo OS (2020) Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med 2020:6175964. https://doi.org/10.1155/2020/6175964CrossRefPubMedPubMedCentral

152.

Ciurea A, Papagiannoulis E, Bürki K et al (2020) Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020:annrheumdis-2020-218705. https://doi.org/10.1136/annrheumdis-2020-218705CrossRef

153.

Jethwa H, Abraham S (2020) Should we be using the Covid-19 outbreak to prompt us to transform our rheumatology service delivery in the technology age? Rheumatology (Oxford) 59:1469–1471. https://doi.org/10.1093/rheumatology/keaa218CrossRef

154.

Gasparyan AY, Misra DP, Yessirkepov M, Zimba O (2020) Perspectives of immune therapy in coronavirus disease 2019. J Korean Med Sci 35:e176. https://doi.org/10.3346/jkms.2020.35.e176CrossRefPubMedPubMedCentral

155.

Kastritis E, Kitas GD, Vassilopoulos D et al (2020) Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. Rheumatol Int 40:1353–1360. https://doi.org/10.1007/s00296-020-04629-xCrossRefPubMedPubMedCentral

156.

Venerito V, Lopalco G, Iannone F (2020) COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatol Int 40:827–828. https://doi.org/10.1007/s00296-020-04566-9CrossRefPubMed

Titel: Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic
verfasst von: Sakir Ahmed
Armen Yuri Gasparyan
Olena Zimba
Publikationsdatum: 03.01.2021
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: Rheumatology International / Ausgabe 2/2021
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-020-04764-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis

Systemic lupus erythematosus may have an early effect on peripheral nerve function in patients without clinical or electrophysiological neuropathy: comparison with age- and gender-matched controls

Increased short-term risk of cardiovascular events in inflammatory rheumatic diseases: results from a population-based cohort

Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends

Early-onset subclinical cardiovascular damage assessed by non-invasive methods in children with Juvenile Idiopathic Arthritis: analytical cross-sectional study